Compare GRF & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GRF | IXHL |
|---|---|---|
| Founded | 1989 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 37.0M |
| IPO Year | N/A | 2024 |
| Metric | GRF | IXHL |
|---|---|---|
| Price | $10.12 | $3.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.7K | ★ 255.9K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $0.16 |
| 52 Week High | $11.85 | $6.39 |
| Indicator | GRF | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 43.89 |
| Support Level | $9.96 | $2.68 |
| Resistance Level | $10.29 | $3.68 |
| Average True Range (ATR) | 0.07 | 0.27 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 71.84 | 28.68 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.